Wei Wang
Directeur/Membre du Conseil chez MingMed Biotechnology Co., Ltd.
Profil
Wei Wang is currently a Member-Supervisory Board at MingMed Biotechnology Co., Ltd.
He obtained an MBA from The University of Hull in 2003.
Postes actifs de Wei Wang
Sociétés | Poste | Début |
---|---|---|
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Directeur/Membre du Conseil | 24/06/2022 |
Formation de Wei Wang
The University of Hull | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
MingMed Biotechnology Co., Ltd.
MingMed Biotechnology Co., Ltd. BiotechnologyHealth Technology MingMed Biotechnology Co., Ltd. engages in the self-discovery and development of innovative drugs. Its core product QA102 is a small molecule drug candidate for the treatment of dry age-related macular degeneration. The company was founded by Guo Ming Huang, Yan Zhang, Xue Bin Liao, Hui Ou Yang, Lai Wei, Miao Liu and Ming Jin on November 26, 2019 and is headquartered in Guangzhou, China. | Health Technology |